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Background: Several in vitro studies suggested the microRNA-29 (miRNA-29) family is involved in regulating HIV-1
and modulating the expression of interleukin (IL)-32, an anti-HIV-1 cytokine.
Methods: To investigate the contribution of the miRNA-29 family to HIV-1 infection in vivo, we compared
miRNA-29 expression in PBMC collected from 58 HIV-1-infected patients, naïve for antiretroviral therapy, and 21
gender- and age-matched HIV-1 seronegative healthy donors, using RT-Taqman assays. The relation between
miRNA-29 levels and HIV-1 viro-immunological markers and the activation rate of antiviral immune response were
also evaluated. In addition, we profiled miRNA-29 expression in CD4+ T lymphocytes and CD14+ monocytes
collected from 5 antiretroviral treated HIV-1 infected patients.
Results: miRNA-29b levels were higher in HIV-1-infected patients than in the control group (p < 0.001). There were
no correlations with either HIV-1 RNA levels or CD4+ T count, whereas a significant correlation was found between
miRNA-29-a/c levels and integrated HIV-1 DNA (miRNA-29a: p = 0.009, r = −0.448; miRNA-29c: p = 0.029; r = −0.381).
When the HIV-1-infected patients were grouped on the basis of their plasma HIV-1 RNA and CD4+ T cell count,
we also found that patients expressing the lowest levels of miRNA-29c showed high viraemia, low CD4+ T cell
count and high levels of integrated HIV-1 DNA. Moreover, miRNA-29b levels were correlated with those of
IL-32nonα (p = 0.028; r = −0.298). Patients expressing higher levels of miRNA-29b showed lower levels of MxA, an
interferon-stimulated gene, also induced by IL-32 (p = 0.006 r = −0.397). Lastly, we found that CD4+ T lymphocytes
and CD14+ monocytes shared similar miRNA-29a/b/c expression patterns but the amount of miRNA-29a/b/c,
IL-32 isoforms and MxA were highly variable in these two cellular subsets.
Conclusions: The miRNA-29 family could influence the clinical progression of HIV-1 infection, the HIV-1 proviral
load and the innate immune response against HIV-1.
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MicroRNAs (miRNAs) are small RNA molecules of ~22
nucleotides involved in the regulation of several bio-
logical processes [1]. Recently, miRNAs have also been
shown to target and inhibit viral gene expression. Sev-
eral interactions between HIV-1 and cellular miRNAs* Correspondence: carolina.scagnolari@uniroma1.it
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unless otherwise stated.have been described, suggesting that altered miRNA
profile expression could contribute to the pathogenesis
of HIV-1 infection and HIV-1 latency in primary CD4+
T lymphocytes [2-5].
Among all the identified miRNAs, the miRNA-29
family has been suggested to play a pivotal role in regu-
lating viral replication. The miRNA-29 family consists
of four closely related members, miRNA-29a, miRNA-
29b-1, miRNA-29b-2 and miRNA-29c, although the
mature sequences of miRNA-29b-1 and miRNA-29b-2
are identical. They are characterized by the same “seedntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cent reports showed that miRNA-29a downregulates
nef expression interfering with HIV-1 replication in
Jurkat cells [7,8]. Moreover it has been shown that
miRNA-29a is highly expressed in human CD4+ T cells
and is able to target the HIV-1 3'UTR region in vitro [9].
MiRNA-29a inhibition enhanced HIV-1 viral produc-
tion and infectivity, whereas expression of miRNA-29a
mimics suppressed viral replication [9]. In agreement
with this observation, Sun et al. found that miRNA-29a/
b, miRNA-155 and miRNA-21 levels were significantly
reduced in HIV-1-infected CD4(+)CD8(−) peripheral
blood mononuclear cells [10]. Furthermore, ex vivo ex-
periments using HIV-1 infected lymphocytes reported a
reduced expression of miRNA-29a, miRNA-29b, and
miRNA-29c [10,11]. However, few studies have investi-
gated the role of the miRNA-29 family in HIV-1
infection in vivo. Houzet and colleagues analyzed the
expression of several miRNAs, including the miRNA-29
family, in PBMC from 36 HIV-1-infected individuals
classified into four classes based on their CD4+ T cell
counts and viral loads. They found miRNA profiles
specific for those different classes of patients that plaus-
ibly correlate stage-specific miRNA alterations with the
in vivo course of HIV-1 infection [12]. Moreover, Witwer
and coworkers analysed miRNA profiles from healthy
individuals, elite HIV-1 controllers, and untreated vir-
aemic HIV-1 patients, also showing that HIV positive
patients have an altered expression of the miRNA-29
family [13].
Interestingly, miRNA-29b was found to be involved in
regulating the expression of interleukin (IL)-32, a cyto-
kine with antiviral properties against HIV-1 [14-17], by
directly targeting the IL-32 mRNA 3'-untranslated re-
gion [18], that can induce IFN-λ1, IFN-β and IFN-
induced genes, such as MxA, PKR and APOBEC3G/3 F
[17-20].
In order to investigate the contribution of the miRNA-29
family to HIV-1 regulation in vivo, we analysed miRNA-
29a/b/c expression in HIV-1 positive patients naïve for
antiretroviral therapy. Then we evaluated the influence of
the miRNA-29 family on the main viro-immunological
markers of HIV-1 infection by analysing the relationship
between miRNA-29 family expression levels and plasma
viraemia, CD4+ T cell count and levels of integrated
HIV-1 DNA, which reflects the establishment of HIV-1
latency [21]. Moreover, to further characterize the rela-
tion between miRNA-29b and IL-32 expression, we
investigated whether miRNA-29 levels influence the
amount of IL-32 and MxA during HIV-1 infection. Fi-
nally, the miRNA-29a/b/c, IL-32 isoforms and MxA
levels were measured in CD4+ T lymphocytes and CD14+
monocytes collected from antiretroviral treated HIV-1 pa-
tients with detectable viremia.Methods
Study population
Peripheral blood samples obtained from 63 HIV-1-infected
patients, both therapy-naïve (n = 58) and HAART-treated
(n = 5), attending the Policlinico Umberto I University
Hospital in Rome were included in this study. All patients
were infected with the HIV-1 subtype B strain. No patients
had any concurrent acute illness or infection including
CMV disease, mycobacterium tubercolosisis, hepatitis B
and C virus infections. The demographic and clinical
characteristics of naïve and treated HIV-1-infected pa-
tients are reported in Table 1. Blood samples from 21
healthy gender- and age-matched individuals were also
included in this study to compare the expression of
miRNA-29a/b/c in naïve HIV-1 positive patients and
healthy subjects.
The study was approved by the ethics committee of
the Policlinico Umberto I Hospital, “Sapienza” University
of Rome and informed consent was obtained from both
HIV-1 positive patients and healthy individuals.
Measurement of HIV-1 RNA and CD4+ T lymphocyte count
HIV-1 viral load was determined by versant HIV-1 RNA
kPCR assay (Siemens Healthcare Diagnostic, Tarrytown
NY, USA) which has a detection limit of 37 copies/ml.
Absolute CD4+ T lymphocyte count was performed by
FACScalibur flow cytometer (Becton Dickinson, San Jose,
CA, USA).
PBMC isolation
PBMC were isolated from naïve and treated HIV-1 in-
fected patients and healthy individuals fresh blood by
Ficoll-Hypaque density gradient centrifugation (Sigma-
Aldrich, St. Louis, MO, USA) and dry pellets of 106 PBMC
were stored at −80°C.
CD4+ T lymphocytes and CD14+ monocytes isolation
CD14+ monocytes and CD4+ T lymphocytes were isolated
from PBMC collected from 5 treated HIV-1-infected pa-
tients by positive selection using the MACS® Technology
(Miltenyi Biotec, Bergisch Gladbach, Germany), according
to the manufacturer's protocol.
TaqMan-based real time RT-PCR technique for microRNAs
MicroRNAs were quantified by real time RT-PCR Taqman
assays (has-miRNA-29a, has-miRNA-29b, has-miRNA-
29c, RNU6B, Applied Biosystems, Monza, Italy). Briefly,
miRNAs were extracted from PBMCs, CD4+ T lympho-
cytes and CD14+ monocytes using the mirVana miRNA
Isolation Kit (Ambion, Austin, TX, USA). Cellular miRNA
purity was evaluated spectrophotometerically at the
absorbance 230, 260 and 280 nm (Varioskan™ Flash
Multimode Reader, Thermo Fisher Scientific Waltham,
MA, USA). Then, miRNAs were reverse transcripted
Table 1 Demographic and clinical characteristics of chronically HIV-1-infected patients and HIV seronegative healthy
individuals
Item Healthy
individuals
(n = 21) (A)
Naïve HIV-1-
infected patients
(n = 58) (B)
Treated HIV-1-
infected patients
(n = 5) (C)
A vs B A vs C
p values p values
Males, n (%) 13 (61.90) 43 (74.13) 4 (80) 0.549 0.809
Mean age ± SD (years) 42.38 ± 11.33 39.43 ± 11.84 44.25 ± 21.51 0.326 0.784
Virus subtype NA B B NA** NA
HIV RNA (copies/ml)* NA 34925 (143–1,405,000) 1446 (80–123,200) NA NA
CD4+ count (cells/mm3)* NA 524 (22–1,200) 400 (350–895) NA NA
Time post infection (months)* NA 12 (1–168) 84 (12–168) NA NA
Duration of HAART (years)* NA NA 6.5 (1–13) NA NA
*Data are expressed as median (range).
Differences in demographic characteristics between HIV-1-infected patients and HIV seronegative healthy individuals were evaluated using Student's t and
Chi-squared tests.
**NA = not applicable.
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cording to the manufacturer's protocols (Applied Biosys-
tems); real time PCR was carried out in a final volume of
20 μl using LightCycler480 instrument (Roche, Basel,
Switzerland). The constitutively expressed RNU6B was
used as an internal control. Expression values of miRNA-
29s were calculated by the comparative threshold cycle
(Ct) method. In particular, the data were analyzed using
the equation 2−deltaCT, where DeltaCT = (CT of target
miRNA − CT of internal control).
TaqMan-based real time RT-PCR technique for mRNA
expression evaluation
mRNA levels of IL-32α, IL-32nonα and MxA were assessed
by real time RT-PCR using the LightCycler480 instrument,
as previously described [17]. Briefly, total RNA was ex-
tracted from PBMC, CD4+ T lymphocytes and CD14+
monocytes using the TRIzol reagent (Invitrogen, Carlsbad,
CA, USA), according to the manufacturer's protocol. The
purity of RNA was evaluated spectrophotometerically at
the absorbance 230, 260 and 280 nm (Varioskan™ Flash
Multimode Reader, Thermo Fisher Scientific Waltham,
MA, USA). Cellular RNA was reverse transcribed by using
High-Capacity cDNA Archive Kit (Applied Biosystems) as
previously specified [22]. Primers and probes for each
gene were added to the Probes Master Mix (Roche, Basel,
Switzerland) at 500 and 250 nM respectively, in a final
volume of 20 μl. The housekeeping gene β-glucuronidase
was used as an internal control. The primers and probe
sequences used for β-glucuronidase gene were the fol-
lowing: Forward 5′-TCTGTCAAGGGCAGTAACCTG-
3′, Reverse 5′-GCCCACGACTTTGTTTTCTG-3′, Probe
5′-(6FAM)TATGTCTTTCGATATGCAGCCAAGTTTT
ACCG3′(TAM)-3′. Gene expression values were calcu-
lated by the comparative Ct method. In particular, data
were analyzed using the equation 2−deltaCT, where Del-
taCT = (CT of target gene − CT of housekeeping gene).TaqMan-based real time RT-PCR technique for HIV DNA
measurement
Total DNA was extracted from PBMC collected from
HIV-1 positive patients using the TRIzol reagent and
then purified using QIAamp DNA Micro Kit (QIAGEN,
Milan, Italy), according to the manufacturer's protocols.
Integrated HIV DNA was quantified using two-step amp-
lification. In the first step, HIV DNA primers designed to
detect host-genome repetitive motifs (Alu) were paired
with HIV-gag specific primers (30 cycle of amplification)
to quantify integrated HIV DNA in patient samples as
previously described [23]. In the second step a real time
PCR for the LTR gene was performed using primers an-
nealing in LTR gene [24]. Human telomerase reverse tran-
scriptase (hTERT) was employed as a housekeeping gene
and amplified in parallel with the HIV-1 gene. To quantify
HIV-1 DNA we used a standard curve (fivefold dilutions
of 8E5 cell DNA) and all samples from each patient were
tested in the same assay. Results were expressed as num-
ber of HIV-1 DNA copies/106 PBMC.
Statistical analysis
Demographic characteristics of HIV-1 positive patients
and healthy donors were compared using Student's t and
Chi-squared tests.
Differences between HIV-1 positive patients and healthy
donors in terms of miRNA-29 expression were analysed
using the Mann–Whitney test. The same test was also
used to compare miRNA-29 expression levels in HIV-1
positive patients divided into two classes on the basis of
the their viral load (class I: HIV RNA >10000 copies/ml;
class II: HIV RNA <10000 copies/ml) and to evaluate any
difference in miRNA-29a/b/c levels and mRNA levels of
MxA, IL-32α and IL-32nonα between CD4+ T lympho-
cytes and CD14+ monocytes.
Spearman's rho coefficient was calculated to assess the
correlation between miRNA-29 levels and 1) the age of
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and CD4+ T cell count; 3) integrated HIV DNA levels;
4) transcript levels of IL-32α, IL-32nonα and MxA.
Differences in miRNA-29 transcript levels in HIV
positive patients stratified into five groups according to
viral load and CD4+ T cell count (Table 2) were analysed
using Kruskal-Wallis test. The same test was also used
to evaluate any differences in expression among miRNA-
29 s in HIV-1-infected individuals and healthy subjects, to
compare miRNA-29 expression levels in HIV-1 positive
patients divided into three groups on the basis of their
CD4+ T cell count (low: <200 CD4+ T cells/mm3; inter-
mediate: 200–500 CD4+ T cells/mm3; high: >500 CD4+ T
cells/mm3) and to analyse differences in expression
among miRNA-29a/b/c in CD4+ T lymphocytes and
CD14+ monocytes.
A p-value less than 0.05 was considered statistically
significant. All analysis were performed with SPSS v.17.0
for Windows.Results
Differential expression of miRNA-29 family members
We evaluated miRNA-29a, miRNA-29b and miRNA-29c
levels in PBMC collected from 58 chronically HIV-1-
infected patients naïve for antiretroviral treatment, and
21 gender- and age- matched HIV-seronegative healthy in-
dividuals. As expected, miRNA-29 transcript levels showed
some degree of individual-to-individual variability both in
untreated chronically HIV-1-infected patients and healthy
donors [coefficient of variation: (HIV-infected patients =
miRNA-29a: 309.97; miRNA-29b: 510.73; miRNA-29c:
320.08); (healthy donors =miRNA-29a: 57.82; miRNA-
29b: 79.15; miRNA-29c: 98.87)] and a significant variation
was observed among the levels of miRNA-29 members in
both HIV-infected patients and healthy donors. In par-
ticular, we observed in both groups that miRNA-29a
levels were higher than those of miRNA-29b/c, miRNA-
29b levels were lower than those of miRNA-29a/c,
whereas miRNA-29c levels showed intermediate levels
of expression (HIV-infected patients: p < 0.001; healthy
donors: p < 0.001) (Figure 1).Table 2 Classifications of HIV-1-infected patients on the
basis of CD4+ T cell count and viral load
Group CD4+ T cell count
(cells/mm3)
Plasma HIV-1 RNA
(HIV RNA copies/ml)
Number of
patients
I 200-500 <10000 8
II >500 <10000 6
III <200 >10000 9
IV 200-500 >10000 11
V >500 >10000 24As shown in Figure 1, miRNA-29b levels were signifi-
cantly higher in HIV-1-infected patients than those mea-
sured in the control group (p < 0.001). No significant
difference was found in miRNA-29a and miRNA-29c
levels between HIV-1-infected patients and healthy indi-
viduals, although we observed a trend toward higher
levels of both miRNA-29 s in HIV-1-infected patients.
The impact of age on miRNA-29 expression was strongly
correlated between miRNA-29b levels and the age of
healthy donors but not with that of HIV positive patients
(p = 0.040; r = 0.574; p = 0.759; r = −0.042). In addition, we
observed that gender was not associated with miRNA-29
levels in either group.
miRNA correlations with plasma viral load or CD4+ T cells
count
We analysed the relationship between miRNA-29 levels
and those of well-known virological and immunological
markers of HIV-1 infection: plasma viral load and CD4+
T cell count.
Results indicated that there were no correlations be-
tween miRNA-29a/b/c and HIV-1 RNA levels (Table 3),
but when the HIV-1-infected patients were divided into
two classes on the basis of the their plasma HIV-1 RNA
(class I: >10000 copies/ml; class II: <10000 copies/ml), the
patients expressing lower levels of miRNA-29c also had
higher levels of viral load (Figure 2, Panel A) (p = 0.038).
Likewise, we failed to detect any significant association
between miRNA-29 expression and CD4+ T count in our
studied group (miRNA-29a: p = 0.865, r = 0.023; miRNA-
29b: p = 0.832, r = 0.029; miRNA-29c: p = 0.731, r = 0.046)
(Table 3) but when the chronically HIV-1-infected pa-
tients were grouped according to their CD4+ T cell
count, the subset with <200 CD4+ T cells/mm3 had lower
levels of miRNA-29c than the subsets with CD4+ T cell
counts of between 200 and 500 and above 500 cells/mm3
(Figure 2, Panel B) (p = 0.019).
These data were also confirmed by a more detailed
analysis based on the division of patients into five groups
of HIV-1 seropositive individuals [i.e. patients with inter-
mediate CD4+ T cell count and low viral load (group I),
high CD4+ T cell count and low viral load (group II), low
CD4+ T cell count and high viral load (group III), inter-
mediate CD4+ T cell count and high viral load (group IV)
and high CD4+ T cell count and high viral load (group
V)] (Table 2). As expected, we found that each group was
characterized by a different level of miRNA-29c expres-
sion (p = 0.019) and that again patients expressing the
lowest levels of miRNA-29c showed high viraemia and
low CD4+ T cell count (group III) (Figure 2, Panel C).
MiRNA correlations with HIV-1 DNA
In an attempt to determine whether differentially expressed
cellular miRNAs could influence HIV-1 proviral load,
Figure 1 Comparison of miRNA-29a/b/c levels in HIV-1-infected patients (n = 58) and gender- and age-matched healthy donors (HD)
(n = 21). MiRNA-29a/b/c levels were analysed in PBMC collected from HIV-1-infected patients and from healthy individuals using real time RT-PCR
assays. MiRNA-29a/b/c levels are expressed as relative expression [ΔCt method] normalized to the levels of the constitutively expressed RNU6B.
The relative quantity of miRNA-29a/b/c levels was calculated by the equation 2 − (ΔCt). Differences between HIV-1-infected patients and healthy
donors in terms of miRNA-29 levels were analysed using the Mann–Whitney test. (°HIV-1-infected patients vs healthy donors: miRNA-29a,
p = 0.251; miRNA-29b, p < 0.0001. miRNA-29c, p = 0.164). Kruskal-Wallis test was used to evaluate differences in expression among miRNA-29a/b/c
in HIV-1-infected individuals and healthy subjects (*HIV-1-infected patients: p < 0.001; **healthy donors: p < 0.001).
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examined for any significant correlation with levels of
integrated HIV-1 DNA measured in PBMC collected
from HIV-infected patients before starting antiretroviral
therapy.Table 3 Relation between miRNA-29a/b/c levels and
viro-immunological parameters, IL-32 isoforms and MxA
in 58 HIV-1-infected patients
Item miRNA-29a miRNA-29b miRNA-29c
p r p r p r
HIV-1 RNA
(copies/ml)
0.079 0.232 0.102 0.445 0.103 0.216
CD4+ T cell count
(cells/mm3)
0.865 0.023 0.832 0.029 0.731 0.046
HIV-1 DNA
(copies/106 cells)
0.009 −0.448 0.176 −0.241 0.029; −0.381
IL-32α NA* NA 0.318 −0.140 NA NA
IL-32nonα NA NA 0.028 −0.298 NA NA
MxA NA NA 0.006 −0.397 NA NA
Spearman’s rho test; significant correlations are highlighted in bold.
*NA = not applicable.Our results indicated a significant negative correl-
ation between miRNA-29a and miRNA-29c expression
levels and those of integrated HIV-1 DNA (miRNA-29a:
p = 0.009; r = −0.448, miRNA-29b: p = 0.176; r = −0.241,
miRNA-29c: p = 0.029; r = −0.381) (Table 3).
Expression of microRNA-29 a/b/c in CD14+ monocytes
and CD4+ T lymphocytes
In an attempt to evaluate whether distinct cellular sub-
sets harbored unique miRNA profiles, the miRNA-29a/
b/c levels were measured in CD4+ T lymphocytes and
CD14+ monocytes collected from HIV-1 infected pa-
tients who didn’t achieve a virological suppression in re-
sponse to antiretroviral therapy. As previously observed
in PBMC of naïve HIV patients, results confirmed that
miRNA-29a levels were higher than those of miRNA-
29b/c, miRNA-29b levels were lower than those of
miRNA-29a/c, whereas miRNA-29c levels showed inter-
mediate levels of expression in both CD4+ T lympho-
cytes and CD14+ monocytes collected from treated
HIV-1 patients (Figure 3). However, the differences in
terms of miRNA-29a/b/c expression reached statistical
significance only when CD14+ monocytes were analyzed
Figure 2 Influence of miRNA-29c levels on viro-immunological
markers of disease progression in HIV-1-infected patients
(n = 58) naïve for antiretroviral therapy. Panel A: miRNA-29c
levels were compared in HIV-1 positive patients divided into two
classes on the basis of their viral load (class I: HIV RNA >10000
copies/ml; class II: HIV RNA <10000 copies/ml). Data were analysed
using the Mann–Whitney test (p = 0.038). Panel B: miRNA-29c levels
were compared in HIV-1 positive patients divided into three groups
on the basis of their CD4+ T cell count (low: <200 CD4+ T cells/
mm3; intermediate: 200–500; CD4+ T cells/mm3; high: >500 CD4+
T cells/mm3). Data were analysed using the Kruskal-Wallis test
(p = 0.019). Panel C: miRNA-29c levels were compared in HIV-1
positive patients divided into five groups on the basis of their viral
load and CD4+ T cell count (Table 2). Data were analysed using the
Kruskal-Wallis test (p = 0.019).
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cytes: p = 0.021). Moreover, we found that some HIV-1 pa-
tients expressed higher levels of miRNA29a-c in CD4 +T
lymphocytes compared to those in CD14+ monocytes
while others manifested an opposite miRNA29a-c pattern
in these two cellular subsets (Figure 3). Due to the high
inter-patients variability of miRNA-29a/b/c expression,
the median values of miRNA-29 a, b, and c were not dif-
ferent between CD4+ T lymphocytes and CD14+ mono-
cytes (Figure 3, CD4+ lymphocytes vs CD14+ monocytes:
miRNA-29a, p = 0.602; miRNA-29b, p = 0.347; miRNA-
29c, p = 0.754).
In vivo relation between miRNA-29b and IL-32
To investigate whether the transcript levels of miRNA-
29b affect IL-32 expression and, in turn, the antiretroviral
response, we measured IL-32 (α and nonα isoforms)
mRNA levels in PBMC collected from 58 HIV-1-infected
patients naïve for antiretroviral treatment. Interestingly,
we found an inverse weak correlation between miRNA-
29b and IL-32nonα levels in HIV positive patients (p =
0.028; r = −0.298) whereas no significant correlation was
found with IL-32α levels (Table 3).
Furthermore we evaluate whether miRNA-29b levels
influence the transcript levels of MxA, a well-established
type I and III IFN-stimulated gene, which is also induced
by IL-32. We found a strong positive correlation be-
tween IL-32nonα and MxA transcript levels (p < 0.001;
r = 0.593) and patients expressing higher levels of miRNA-
29b showed lower levels of MxA (p = 0.006 r = −0.397)
(Table 3). Then, we tried to establish which cellular subset,
CD4+ T lymphocytes and CD14+ monocytes, could be re-
sponsible of the relationships observed between miRNA-
29s, IL-32 and MxA in PBMC of naïve HIV-1 patients. As
previously observed for miRNA-29a/b/c levels, the expres-
sion of IL-32 isoforms (α and nonα) and MxA exhibited a
high degree of variability in CD4+ T lymphocytes and
CD14+ monocytes and they were not different in these
cellular subsets (Figure 4, CD4+ lymphocytes vs CD14+
Figure 3 Expression of miRNA-29a/b/c in CD14+ monocytes and CD4+ T lymphocytes collected from treated HIV-1-infected patients
with detectable viremia (n = 5). miRNA-29a/b/c levels were analysed in CD14+ monocytes and CD4+ T lymphocytes using real time RT-PCR
assays. Panel A-E. Patient 1: viral load = 146 HIV RNA copies/ml; CD4+ T cell count = 450 cells/mm3. Patient 2: viral load = 80 HIV RNA copies/ml;
CD4+ T cell count = 350 cells/mm3. Patient 3: viral load = 3278 HIV RNA copies/ml; CD4+ T cell count = 340 cells/mm3. Patient 4: viral load =
123,200 HIV RNA copies/ml; CD4+ T cell count = 400 cells/mm3. Patient 5: viral load = 1446 HIV RNA copies/ml; CD4+ T cell count = 895
cells/mm3. Panel F. Differences between CD14+ monocytes and CD4+ T lymphocytes in terms of miRNA-29 levels collected from treated
HIV-1-infected patients were analysed using the Mann–Whitney test (CD4+ T lymphocytes vs CD14+ monocytes: miRNA-29a, p = 0.602; miRNA-29b,
p = 0.347; miRNA-29c, p = 0.754). Kruskal-Wallis test was used to evaluate differences in expression among miRNA-29a/b/c in HIV-1-infected individuals
and healthy subjects (CD4+ T lymphocytes: p = 0.114; *CD14+ monocytes: p = 0.021).
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Discussion and conclusions
Recent reports have indicated the miRNA-29 family as a
putative regulator of key processes against HIV-1 infection.
Thus, we compared the expression profile of miRNA-29a,
miRNA-29b and miRNA-29c in HIV-1-infected patients
and healthy donors, and evaluated whether and how dif-
ferences in expression could influence the clinicalprogression of HIV-1 infection and the antiviral im-
mune response.
Interestingly, we found a significant positive correl-
ation between miRNA-29b levels and the age of healthy
donors but not with that of HIV positive patients, sug-
gesting an age-dependent regulation of miRNA-29b ex-
pression in healthy individuals. In agreement with this
observation, Zhang et al. reported that mechanisms of
transcriptional regulation of miRNA transcripts and al-
tered expression of Argonaut proteins contribute to age-
Figure 4 mRNA expression of MxA, IL-32α and IL-32nonα in CD14+ monocytes and CD4+ T lymphocytes collected from treated
HIV-1-infected patients with detectable viremia (n = 5). mRNA levels of MxA, IL-32α and IL-32nonα were analysed using real time RT-PCR
assays. mRNA levels are expressed as relative expression [ΔCt method] normalized to the levels of the constitutively expressed β-glucuronidase
gene. Panel A-E. Patient 1: viral load = 146 HIV RNA copies/ml; CD4+ T cell count = 450 cells/mm3. Patient 2: viral load = 80 HIV RNA copies/ml;
CD4+ T cell count = 350 cells/mm3. Patient 3: viral load = 3278 HIV RNA copies/ml; CD4+ T cell count = 340 cells/mm3. Patient 4: viral load = 123,200
HIV RNA copies/ml; CD4+ T cell count = 400 cells/mm3. Patient 5: viral load = 1446 HIV RNA copies/ml; CD4+ T cell count = 895 cells/mm3. Panel F.
Differences in mRNA levels between CD14+ monocytes and CD4+ T lymphocytes collected from treated HIV-1-infected patients (n = 5) were analysed
using the Mann–Whitney test (CD4+ T lymphocytes vs CD14+ monocytes: MxA, p = 0.465; IL-32α, p = 0.347; IL-32nonα, p = 0.754).
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miRNA* strands [25]. The loss of correlation between
age and miRNA-29b levels observed in the HIV-infected
patients could be explained as a consequence of viral
pathogenesis: HIV-1 infection in vivo is expected to
exert physiologic effects on T-cell function which could
be reflected in significant miRNA changes. Directlyrelated to this, we found that levels of miRNA-29b ex-
pression were significantly higher in HIV-1-infected pa-
tients compared to the control group. No significant
correlation was found between miRNA-29a and miRNA-
29c expression levels and the age of either healthy do-
nors or HIV-1 positive patients. We also failed to detect
any significant difference between miRNA-29a and
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and HIV-1 positive patients, although we did observe a
trend toward higher levels of both miRNAs in HIV-1-
infected patients. This could be explained by the fact that
although the three mature members of the miRNA-29
family share a common seed region sequence and are pre-
dicted to target largely overlapping sets of genes, they ex-
hibit differential regulation in several cases and different
subcellular distribution [26]. In addition, their stable ex-
pression levels are likely to depend on expression of the
two clusters, alternative splicing of primary RNA and dif-
ferential decay, all factors which may vary in a cell-specific
manner [6].
In line with our results, it was recently reported that
HIV-1-infected patients are characterized by an altered
miRNA expression profile compared to healthy donors.
Witwer and coworkers described an altered PBMC miRNA
profile in elite suppressors and untreated viraemic patients
compared to uninfected controls. However, they found that
among miRNAs with significant expression changes ex-
pression levels were more often lower in viraemic individ-
uals. For example, control PBMC had higher mean levels
than viraemic PBMC of all miRNA-29 family members
[13]. Furthermore, Houzet and colleagues profiled miRNA
expression in PBMC from 36 HIV-1 seropositive individ-
uals categorized into four classes based on their CD4+ T
cell counts and viral loads. They found that specific
miRNA signatures, including miRNA-29s, can be observed
for each class [12]. Having observed that HIV-1 infection is
associated with altered patterns of miRNA-29 expression,
we tried to evaluate whether this phenomenon would
affect the plasma viral load and CD4+ T cell count. In a
first analysis, we did not find any significant association be-
tween miRNA-29 expression levels and plasma HIV RNA
levels. This observation is in agreement with Witwer et al.,
who found no correlations with viral load in the viraemic
group, although miRNA-29a has been reported to silence
HIV-1 in vitro [7-9]. We also failed to find any significant
association between miRNA-29s expression and CD4+ T
cell count, whereas Witwer et al.’s study found both
negative and positive correlations between several miR-
NAs, including miRNA-29a, and CD4+ T cell counts.
However, this correlation was only present when elite
suppressor, not included in our study population, and
viraemic patients were grouped together. To further
analyze the relationship between miRNA-29s expression
and the viro-immunological markers of HIV-1 infection,
we grouped the chronically HIV-1-infected patients on
the basis of their plasma HIV RNA and CD4+ T cell
count, to represent different stages of the infection. Al-
though there was no significant difference in expression
levels of miRNA-29a and miRNA-29b between patients
with more or less severe HIV-1 infection, interestingly
we found that miRNA-29c levels were related to bothviral load and CD4+ T cell count. Indeed, patients ex-
pressing lower levels of miRNA-29c also had higher levels
of viraemia and lower levels of CD4+ T cell count, sug-
gesting a strong relation between miRNA-29c and these
clinical markers of HIV-1 infection. This relation may
imply that baseline lower levels of miRNA-29c expres-
sion in some individuals could negatively influence the
progression of HIV-1 infection. Alternatively, the pres-
ence of HIV-1 or the host response against HIV-1 may
reduce miRNA-29c expression, by inducing CD4+ T-
cell depletion.
Several studies reported that the onset of HIV-1 la-
tency could be influenced by cellular miRNA [27], but
the role of miRNA-29s in controlling this phenomenon
has not been well characterized. For the first time to our
knowledge, our results show that miRNA-29c expression
levels are significantly and negatively correlated with
levels of integrated HIV-1 DNA. Thus, in our study
population, patients with lower levels of miRNA-29c not
only showed higher levels of plasma viraemia and a lower
CD4+ T cell count, but also had higher levels of HIV-1
DNA, confirming the association between low levels of
expression of miRNA-29c and poor prognosis. Probably,
the higher rate of proliferation observed in patients with a
lower CD4+ T cell count led to a larger overall reservoir
size. On the other hand, we cannot exclude that by sup-
pressing HIV-1 production miRNA-29a could regulate
viral gene expression, modulating the viral life cycle and
promoting the onset and maintenance of latency. More-
over, given that we found the same significant trend in
miRNA-29a levels, miRNA-29a and miRNA-29c could
influence HIV-1 latency by a common mechanism. How-
ever, miRNA-29a-c and HIV-1 DNA integrated levels
were quantified only in total PBMCs, and may have
missed differences in various cell types, such as resting
central memory T cells and translational memory T
cells, which serve as major sites for HIV-1 latency [28].
Interestingly, in this study we also found that miRNA-
29a/b/c signature was similar in both CD4+ T lympho-
cytes and CD14+ monocytes to that previously observed
in total PBMC of naive HIV-1 infected patients. Further-
more, we observed that the amount of miRNA-29a-c
measured in CD4+T lymphocytes and CD14+monocytes
were highly variable and not different in these cellular sub-
sets. These findings indicate that both CD4+ T lympho-
cytes and CD14+ monocytes can actively contribute to the
production of miRNA-29 a/b/c during HIV-1 infection
and suggest that CD4+ T cell alteration does not explain
all differential expression of miRNA-29a/b/c recorded in
HIV-1 patients. In agreement, Witwer KW et al. reported
that some cellular miRNAs that have been found at high
levels across PBMC subsets or are even enriched in CD4+
T-cell subsets [29]-and would therefore be expected to
decline along with CD4+ T cells were, to the contrary,
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ther studies are needed to characterize the effects of
HIV-1 on miRNA-29s expression in PBMC and specific
cell types both in vivo and, as far as possible, in primary
culture ex vivo.
Our study is also the first to evaluate the influence of
miRNA-29b on the expression of different isoforms of a
novel anti-HIV cytokine, namely IL-32, during chronic
HIV-1 infection. Given that six isoforms of IL-32 have
been identified, we chose to detect IL-32α and the other
IL-32 isoforms (β, γ, δ, ε, ζ) separately, using a real time
PCR assay previously developed in our laboratory [17].
We found a weak inverse correlation between miRNA-
29b and IL-32nonα levels in PBMC collected from HIV-
1-infected patients, whereas no significant correlation
was found with IL-32α levels, suggesting that miRNA-
29b specifically targets other isoforms of IL-32. Our data
are in agreement with those reported by Li and coworkers,
who showed that miRNA-29b and IL-32 mRNA levels
were negatively correlated in PBMC samples from HBV-
infected patients [18]. However, further analyses will be
needed to confirm the presence of these relationships with
a larger sample size of HIV-1 infected patients and to
identify which specific isoform/isoforms of IL-32 is/are
regulated by miRNA-29b.
One of the tools used by IL-32 to fight viruses, includ-
ing HIV-1, is its ability to induce MxA expression [17].
We previously demonstrated that IL-32γ can significantly
induce expression of IFN stimulating genes (ISGs), includ-
ing MxA, in PBMC collected from healthy donors, al-
though to a lower extent than IFNα2b [17]. Moreover,
recent reports showed that IL-32 exerts its antiviral activity
through the induction of IFN-λ1 and IFN-β expression,
which in turn act by inducing ISGs [18,19]. Thus, we eval-
uated the influence of miR-29b expression on the tran-
script levels of MxA in HIV-infected patients. As expected,
patients expressing higher levels of miRNA-29b showed
lower levels of MxA, confirming that MxA induction is
regulated by IL-32, both directly and through a type I and
III IFN-mediated pathway. Interestingly, we also found that
CD4+ T lymphocytes as well as CD14+ monocytes were
capable of producing miRNA-29b, IL-32 isoforms and
MxA indicating that these cellular subsets were involved in
the activation of the IL-32- and IFN-mediated antiviral re-
sponse during HIV-1 infection. Taken together, these data
suggest that the up-regulation of miRNA-29b observed in
HIV-infected patients has a strong negative impact on the
antiviral immune response and that the virus may take ad-
vantage of the change in the normal cell miRNA profile.
On the other side, considering the complex and to some
extent controversial role played by IFN-α/β in HIV-1 dis-
ease [30], our results indicated that miRNA-29b would
contribute to the regulation of the rate of IFN activation by
suppressing the IL-32 nonα isoforms levels during HIV-1infection. However, several cellular pathways are regu-
lated by both miRNA-29 and IFN subtypes highlighting
the complexity of phenomenon analyzed [31-33]. In this
regards, miRNA-29 can regulate and activate T-box
transcription factors and IFN-γ production in helper T
cells [31]. Furthermore, epigenetic changes mediated by
miRNA-29 can induce IFN-λ1 production during viral
infection and the suppression of the IFN-α receptor
expression can be mediated by miRNA-29 in thymic
epithelium to increase the threshold for infection-
associated thymic involution [32,33].
In conclusion, we showed that transcription levels of all
mature members of the miRNA-29 family are highly vari-
able in HIV-1-infected patients and that the miRNA-29b
expression pattern is altered in this population compared
to healthy individuals. We also found that miRNA-29c ex-
pression is closely correlated with markers of HIV-1 clin-
ical outcome, such as plasma viral load and CD4+ T cell
count, and that both miRNA-29a and miRNA-29c could
affect the HIV-1 proviral load. In addition, we demon-
strated that miRNA-29b levels influence the rate of IL-
32nonα and MxA expression, highlighting the role of the
miRNA-29 family as a double-edged sword during in vivo
HIV-1 infection.
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